Edwards Lifesciences (EW) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended March 2025, Edwards Lifesciences (EW) reported revenue of $1.41 billion, down 11.6% over the same period last year. EPS came in at $0.64, compared to $0.66 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.4 billion, representing a surprise of +0.71%. The company delivered an EPS surprise of +6.67%, with the consensus EPS estimate being $0.60.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Edwards Lifesciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- Europe: $341.80 million compared to the $357.01 million average estimate based on two analysts. The reported number represents a change of -7.1% year over year. Net Sales- Outside of the United States: $573.80 million versus $573.77 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -12.7% change. Net Sales- United States: $838.90 million versus the two-analyst average estimate of $849.03 million. The reported number represents a year-over-year change of -10.8%. Net Sales- Japan: $81.80 million compared to the $96.40 million average estimate based on two analysts. The reported number represents a change of -26.2% year over year. Net Sales- Rest of World: $150.20 million versus $120.36 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -16% change. Net Sales by Product Group- Transcatheter Aortic Valve Replacement: $1.05 billion compared to the $1.03 billion average estimate based on eight analysts. The reported number represents a change of +3.8% year over year. Net Sales by Product Group- Surgical Structural Heart: $250.90 million versus $254.51 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -5.7% change. Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies: $115.20 million versus the eight-analyst average estimate of $113.82 million. The reported number represents a year-over-year change of +58%. View all Key Company Metrics for Edwards Lifesciences here>>>Shares of Edwards Lifesciences have returned -0.9% over the past month versus the Zacks S&P 500 composite's -6.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Edwards Lifesciences Corporation (EW): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks